Prevention and control of chemotherapy-induced nausea and vomiting;Prevención y control de las náuseas y los vómitos inducidos por quimioterapia

Medicina Clinica

Volumn 126, Issue 4, 2006, Pages 143-151

  Gómez Raposo, César ^a   Feliú Batle, Jaime ^a   González Barón, Manuel ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Chemotherapy; Emesis; Nausea; Vomiting

Indexed keywords

ALTRETAMINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; GRANISETRON; IFOSFAMIDE; IRINOTECAN; MEPREDNISONE; METHOTREXATE; METOCLOPRAMIDE; MITOXANTRONE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONOSETRON; PROCARBAZINE; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; TROPISETRON; UNINDEXED DRUG;

CHEMOTHERAPY INDUCED EMESIS; DISTRESS SYNDROME; DRUG EFFICACY; HUMAN; NAUSEA; NURSE; PATIENT COMPLIANCE; PHYSICIAN; QUALITY CONTROL; REVIEW; TREATMENT OUTCOME;

EID: 33644543081     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13084022     Document Type: Review

References (96)

1. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203-9.
2. Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J. Quality of life studies in chemotherapy-induced emesis. Oncology. 1996;53 Suppl 1:92-5.
3. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, et al. On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;72:189-95.
4. Grumberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after moderm antiemetics. Cancer. 2004;100:2261-8.
5. Kris MG. Why do we need another antiemetic? Just Ask. J Clin Oncol. 2003;21:4077-80.
6. Morrow GR. Chemotherapy-related nausea and vomiting: etiology and management. Cancer. 1989;39:89-104.
7. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985;3: 1379-84.
8. Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs. 1996;52:639-48.
9. Boakes RA, Tarrier N, Barnes BW, Tattersall MH. Prevalence of anticipatory nausea nad other side-effects in cancer patients receiving chemotherapy. Eur J Cancer. 1993;29A:866-70.
10. Borison HL, Wang SC. Physiology and pharmacology of vomiting. Pharmacol Rev. 1953;5:193-7.
11. Carpenter DO. Neural mechanisms of emesis. Can J Physiol Pharmacol. 1990;68:230-8.
12. Bountra C, Gale JD, Gardner CJ, Jordan CC, Kilpatrick GJ, Twissell DJ, et al. Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Oncology. 1996;53: S102-10.
13. Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, et al. The antiemetic effects of CP-99,994 in the ferret and the dog: role of the NK-1 receptor. Br J Pharmacol. 1995;115:84-8.
14. Andrews PL, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci. 1988;9:334-41.
15. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy induced nausea and vomiting. Drugs. 2004;64:777-94.
16. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822-30.
17. Hesketh PJ, Plagge P, Bryson JC. Single dose ondansetron for the prevention of acute cisplatin-induced emesis: Analysis of efficacy and prognostic factors. En: Bianchi L, Grelot AD, Miller GL, editors. Mechanism and control of emesis. London: John Libby Eurotext Ltd; 1992. p. 235.
18. Pollera CF, Giannarelli D. Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer. 1989;64:1117-22.
19. Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors for post-chemotherapy nausea an vomiting. Support Care Cancer. 1994;2:161-6.
20. Olver IN. Antiemetic study design: Desirable objectives, stratifications and analyses. Br J Cancer. 1992;Suppl 19:530-8.
21. Morrow GR, Roscoe JA, Hickok JT, Stern RM, Pierce HI, King DB, et al. Initial control of chemotherapy-induced nausea and vomiting in patients quality of life. Oncology. 1998; 12:32-7.
22. Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs. 1998;55:173-89.
23. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonist according to cytochrome P-450 2D6 genotypes. J Clin Oncolo. 2002;20:2805-9.
24. Tremblay PB, Kaiser R, Sezer O, Rosier N, Schelenz C, Possinger K, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol. 2003;21:2147-53.
25. Oliver IN, Simon RM, Aisner J. Antiemetic studies: A methodological discussion. Cancer Treat Rep. 1986;70:555-61.
26. Jordan NS, Schauer PK, Schauer A, Nightingale C, Golub G, Martin RS, et al. The effect of administration rate on cisplatin-induced emesis. J Clin Oncol. 1985;3:559-65.
27. Italian Group for Antiemetic Research: Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med. 2000;342: 1554-9.
28. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic contol. Oncologist. 2003;8:187-98.
29. Morrow GR, Roscoe JA, Kirshner JJ, Hynes HE, Rosenbluth RJ. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer. 1998;6:244-50.
30. Laszlo J. Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev. 1982;9 Suppl B:3-9.
31. Lindley CM, Bernard S, Fields SM. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol. 1989;7:1142-9.
32. Aapro M. Methodological issues in antiemetic studies. Invest New Drugs. 1993;11:243-6.
33. Hesketh PJ, Kris MG, Grumberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15:103-9.
34. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999;4:191-6.
35. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Lawrence WC, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-94.
36. Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C, et al. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer. 1994;4:1945-52.
37. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, et al. Commparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol. 1995;13:1242-9.
38. Bonneterre J, Hecquet B. Granisetron (IV) compared with ondnsetron (IV plus oral) in the prevention of nausea and vomiting induced by moderately-emetogenic chemotherapy. A cross-over study. Bull Cancer. 1995;822:1038-43.
39. Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, Kris M, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol. 1996;14:2242-9.
40. Loiters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, et al. Phase III double-blind comparison of dolasetron mesylate and ondasetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997;15:2966-73.
41. Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Riviere A, et al. A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high-dose cisplatin chemotherapy. Eur J Cancer. 1996;32A: 807-15.
42. Del Giglio A, Scares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer. 2000;89:2301-9.
43. Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA, Gralla RJ. Consensus proposal for 5-HT3 antagonists in the prevetion of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer. 1998;6:237-44.
44. Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomized, parallel group study. Ondansetron Study Group. Br J Cancer. 1992;66:237-42.
45. Beck TM, Hesketh PJ, Madajwicz S, Navari RM, Pendergrass K, Lester EP, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992;10:1969-79.
46. Eittenger DS, Eisenberg Pd, Fitts D, Friedman C, Wilson-Lynch K, Yocom K. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer. 1996;78:144-51.
47. Pérez EA, Hesketh PJ, Sandbach J, Reeves J, Chawla S, Markman M, et al. Comparison of single-dose oral granisetron versus intravenous ondan-setron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998;16:754-60.
48. Asif M, Siddiqui A, Scott LJ. Palonosetron. Drugs. 2004;64:1125-32.
49. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron. Cancer. 2003;98:2473-80.
50. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves pevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomizaed phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14: 1570-80.
51. Aapro MS, Bertoli, Lordick F. Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy [abstract]. Support Care Cancer. 2003;11:17a.
52. Quintana E, García-Zaragoza E, Espluges JV. Tratamiento del vómito en 1a quimioterapia: Papel de los antagonistas 5HT3. GH continuada. 2002; 1:74-80.
53. Jordan K, Kasper C, Schmoll H-J. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer. 2005;41:199-205.
54. Herrstedt J, Aapro MS, Smyth JF, Del Fabero. Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer. 1998;6:204-12.
55. Darmani NA, Jonson JC. Central and peripheral mechanisms contribuye to the antiemetic actions of delta-9 tetrahydrocannabinol against 5-hydroxitrytophan-induced emesis. Eur J Pharmacol. 2004;488:201-12.
56. Tramer MR, Carroll D, Campbell FA, Reynolds JM, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:16-21.
57. Levitt M, Faiman C, Hawks R, Wilson A. Randomized double blind comparison of delta-9 tetrahydrocannabinol (THC) and marihuana as chemotherapy antiemetics. ASCO Abstracts. 1984;3:91.
58. Heron JF, Goedhals L, Jordaan JP, Cunningham J, Cedar E. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. Ann Oncol. 1994;5:579-87.
59. Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Eur J Cancer. 1990;26 Suppl 1:S33.
60. Warr D, Wilan A, Venner P, Pater J, Kaizer L, Laberge F, et al. A randomized, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial. Eur J Cancer. 1992;29A:33.
61. Chevallier B, Cappelaere P, Splinter T, Fabbro M, Wendung JL, Cals L, et al. A double-blind multicentre comparison of intravenous dolasetron mesilae and metoclopramide in the prevention of nausea and vomiting in cancer patients reciving high-dose cisplatin chemotherapy. Support Care Cancer. 1997;5:22.
62. Jantunen IT, Flander MK, Heikkinen MI, Kuoppala TA, Teerenhovi L, Kataja W. Comparison of ondansetron with customary treatment in the prophylaxis of nausea and emesis induced by non-cisplatin containing chemotherapy. Acta Oncol. 1993;32:413-5.
63. Jantunen IT, Kataja W, Muhonen TT. An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional antiemetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer. 1997;33:66-74.
64. Navari RM, Province WS, Perrine GM, Kilgore JR. Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. Cancer. 1993;72:583-6.
65. Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Eng J Med. 1995;332:1-11.
66. Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991;9:675-83.
67. Smyth JF, Coleman RE, Nicolson M, Gallmeier WM, Leonard RC, Cornbleet MA, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ. 1991;303:1423-32.
68. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker U, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of nausea and vomiting associated with high-dose cisplatin. J Clin Oncol. 1994;12:596-604.
69. Joss RA, Bacchi M, Buser K, Kirchner V, Neuenschwaner H, Orth B, et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 1994;5:253-60.
70. Heron HF. Single-agent granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone. Semin Oncol. 1995;22 Suppl 10:24-30.
71. Roila F. Control of acute cisplatin-induced emesis over repeat courses of chemotherapy. Italian Group for Clinical Research. Oncology. 1996;53 Suppl 1:65-72.
72. Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous dosis of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol. 1998;16:2937-42.
73. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatino or cyclophosphamide. J Clin Oncol. 2004;22:725-32.
74. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG. The oral neurokinin 1 antagonists aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4105-13.
75. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldrige K, Hippie A, et al. Addition of the neurokinin 1 receptor antagonists to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-101.
76. Warr DG, Eisenberg P, Hesketh PJ, Grumber SM, Gralla RJ, Muss HB, et al. Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: a randomized double-blind trial in 866 patients. Proc Am Soc Clin Oncol. 2004;23:730s.
77. Pater JL, Loiters WS, Zee B, Dempsey E, Walde D, Moquin JP, et al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol. 1997;8:181-9.
78. Koo Wh, Ang PT. Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol. 1996;7:71-4.
79. Goedhals L, Heron JF, Lleisbauer JP, Pagani O, Sessa C. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol. 1998;9:661-6.
80. Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol. 1996;7:945-54.
81. Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol. 1995;13:2408-16.
82. Laitrelle J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Trials Group. J Clin Oncol. 1998; 16:1174-85.
83. Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol. 1997;15:124-30.
84. Tsukada H, Hirose T, Yokohama A, Kurita Y. Randomized comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer. 2001;37: 2398-404.
85. Cancer Care Ontario Practice Guidelines Initiative: Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Practice Guideline Repor 12-3. Disponible en: http://www. cancercare.on.ca/pdf/ fulll2_3.pdf
86. Geling O, Eichler HG. Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications. J Clin Oncol2E 2005;23:1289-94.
87. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989;7:108-16.
88. Campora E, Giudici S, Merlini L, Rubagotti A, Rosso R. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide- doxorrubicin chemotherapy and maintenance of antiemetic effect at subsequent courses. Am J Clin Oncol. 1994; 17:522-6.
89. Morrow GR, Morrell C. Behavioural treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Eng J Med. 1982; 307:176-80.
90. Fallowfield LJ. Behavioural interventions and psychological aspects of care during chemotherapy. Eur J Cancer. 1992;28A Suppl 1:S39.
91. De Witt A, De Boer AC, Vd Linden GH, Stoter G, Sparreboom A, Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001;85:1099-110.
92. Sigsgaard T, Herrstedt J, Christensen P, Andersen O, Dombernowsky P. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy. Support Care Cancer. 2000;8:233-40.
93. Guttuso T Jr, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet. 2003;361: 1703-11.
94. Hainsworth JD. The use of ondansetron in patients receiving multiple-day cisplatin regimens. Semin Oncol. 1992;19:48-56.
95. Rath U, Upadhyaya BK, Arechavala E, Bockhmann H, Dearnaley D, Droz JP, et al. Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology. 1993;50:168-75.
96. Roscoe JA, Morrow GR, Hickok JT, Stern RN. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage. 2000;20:113-21.